EA201300470A1 - Антитела - Google Patents
АнтителаInfo
- Publication number
- EA201300470A1 EA201300470A1 EA201300470A EA201300470A EA201300470A1 EA 201300470 A1 EA201300470 A1 EA 201300470A1 EA 201300470 A EA201300470 A EA 201300470A EA 201300470 A EA201300470 A EA 201300470A EA 201300470 A1 EA201300470 A1 EA 201300470A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cdh17
- antibodies
- cancer
- methods
- nucleic acid
- Prior art date
Links
- 102100024152 Cadherin-17 Human genes 0.000 abstract 5
- 101000762247 Homo sapiens Cadherin-17 Proteins 0.000 abstract 5
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40509010P | 2010-10-20 | 2010-10-20 | |
| PCT/US2011/001787 WO2012054084A2 (en) | 2010-10-20 | 2011-10-19 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201300470A1 true EA201300470A1 (ru) | 2014-05-30 |
Family
ID=45975790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201300470A EA201300470A1 (ru) | 2010-10-20 | 2011-10-19 | Антитела |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130259878A1 (enExample) |
| EP (1) | EP2629796A4 (enExample) |
| JP (1) | JP2014502955A (enExample) |
| KR (1) | KR20130138802A (enExample) |
| CN (1) | CN103534268B (enExample) |
| AU (1) | AU2011318574B2 (enExample) |
| BR (1) | BR112013009551A2 (enExample) |
| CA (1) | CA2815041A1 (enExample) |
| EA (1) | EA201300470A1 (enExample) |
| IL (1) | IL225571A0 (enExample) |
| MX (1) | MX2013004476A (enExample) |
| NZ (1) | NZ610091A (enExample) |
| SG (1) | SG189835A1 (enExample) |
| WO (1) | WO2012054084A2 (enExample) |
| ZA (1) | ZA201302459B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703949C1 (ru) * | 2018-04-27 | 2019-10-22 | Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) | Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
| IN2015DN01967A (enExample) * | 2012-09-19 | 2015-08-14 | Abbvie Biotherapeutics Inc | |
| CN113817060B (zh) * | 2016-01-09 | 2024-03-08 | 嘉立医疗科技(广州)有限公司 | 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 |
| EP3360898A1 (en) * | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| EP3784990A4 (en) * | 2018-04-26 | 2022-06-22 | The Trustees of the University of Pennsylvania | COMPOSITIONS AND METHODS FOR DETECTING TUMOR-RELATED ANTIBODIES AND ANTIGENS |
| CN112512575B (zh) * | 2018-05-16 | 2024-08-06 | 嘉立医疗科技(广州)有限公司 | 双特异性抗体组合物及其使用方法 |
| US20210116456A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Compositions and methods for diagnosis and treatment of cancer |
| WO2023015169A1 (en) * | 2021-08-02 | 2023-02-09 | Tavotek Biotech (Suzhou) Ltd | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof |
| WO2024100294A1 (en) | 2022-11-11 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Cdh17 car |
| CN120917040A (zh) * | 2023-01-31 | 2025-11-07 | 毕格哈特生物科学公司 | 抗cdh17抗体及其用途 |
| TW202448962A (zh) * | 2023-02-23 | 2024-12-16 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段和使用方法 |
| TW202509083A (zh) * | 2023-05-24 | 2025-03-01 | 大陸商普眾發現醫藥科技（上海）有限公司 | 抗體及其抗體－藥物偶聯物 |
| WO2025061181A1 (en) * | 2023-09-22 | 2025-03-27 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibodies and uses thereof |
| CN120230211A (zh) * | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| WO2025242100A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1996040942A1 (en) * | 1995-06-07 | 1996-12-19 | Cytel Corporation | Humanized antibodies to e-selectin |
| KR101077001B1 (ko) * | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1354896B1 (en) * | 2000-12-28 | 2010-02-10 | Kyowa Hakko Kirin Co., Ltd. | Monoclonal antibody directed against the human bst2 antigen |
| IL149820A0 (en) * | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| JP2006089471A (ja) * | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| RU2404193C2 (ru) * | 2005-03-25 | 2010-11-20 | Дженентек, Инк. | Способ лечения опухоли у субъекта |
| US8535677B2 (en) * | 2006-06-06 | 2013-09-17 | Oxford Biotherapeutics, Ltd. | Antibody drug conjugate treatment of colorectal cancer |
| WO2009116670A1 (ja) * | 2008-03-17 | 2009-09-24 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| EP2399934B1 (en) * | 2009-02-20 | 2017-09-06 | The University of Tokyo | Novel monoclonal antibody, and use thereof |
| JP5748653B2 (ja) * | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法 |
| SG10201401604VA (en) * | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
-
2011
- 2011-10-19 EA EA201300470A patent/EA201300470A1/ru unknown
- 2011-10-19 JP JP2013534894A patent/JP2014502955A/ja active Pending
- 2011-10-19 SG SG2013025242A patent/SG189835A1/en unknown
- 2011-10-19 NZ NZ610091A patent/NZ610091A/en not_active IP Right Cessation
- 2011-10-19 AU AU2011318574A patent/AU2011318574B2/en not_active Ceased
- 2011-10-19 WO PCT/US2011/001787 patent/WO2012054084A2/en not_active Ceased
- 2011-10-19 CA CA2815041A patent/CA2815041A1/en not_active Abandoned
- 2011-10-19 US US13/880,320 patent/US20130259878A1/en not_active Abandoned
- 2011-10-19 CN CN201180050390.8A patent/CN103534268B/zh not_active Expired - Fee Related
- 2011-10-19 EP EP11834758.2A patent/EP2629796A4/en not_active Withdrawn
- 2011-10-19 BR BR112013009551A patent/BR112013009551A2/pt not_active IP Right Cessation
- 2011-10-19 KR KR1020137012771A patent/KR20130138802A/ko not_active Withdrawn
- 2011-10-19 MX MX2013004476A patent/MX2013004476A/es unknown
-
2013
- 2013-04-04 IL IL225571A patent/IL225571A0/en unknown
- 2013-04-05 ZA ZA2013/02459A patent/ZA201302459B/en unknown
-
2014
- 2014-11-20 US US14/549,176 patent/US20150093392A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703949C1 (ru) * | 2018-04-27 | 2019-10-22 | Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) | Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011318574B2 (en) | 2016-03-03 |
| ZA201302459B (en) | 2014-01-29 |
| CA2815041A1 (en) | 2012-04-26 |
| KR20130138802A (ko) | 2013-12-19 |
| NZ610091A (en) | 2015-02-27 |
| JP2014502955A (ja) | 2014-02-06 |
| CN103534268B (zh) | 2016-05-18 |
| WO2012054084A3 (en) | 2013-10-17 |
| US20130259878A1 (en) | 2013-10-03 |
| EP2629796A4 (en) | 2015-01-28 |
| IL225571A0 (en) | 2013-06-27 |
| CN103534268A (zh) | 2014-01-22 |
| MX2013004476A (es) | 2013-06-28 |
| AU2011318574A1 (en) | 2013-05-02 |
| US20150093392A1 (en) | 2015-04-02 |
| BR112013009551A2 (pt) | 2016-07-12 |
| EP2629796A2 (en) | 2013-08-28 |
| WO2012054084A2 (en) | 2012-04-26 |
| SG189835A1 (en) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201300470A1 (ru) | Антитела | |
| EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| EA201101242A1 (ru) | Полностью человеческие антитела, специфические для cadm1 | |
| EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
| EA201000238A1 (ru) | Антигенсвязывающие белки для il-18 рецептора и их применение | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| UA116766C2 (uk) | Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3 | |
| MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
| EA201201000A1 (ru) | Способы лечения колоректального рака | |
| PH12016500580B1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
| EA201390744A1 (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| EA201390467A1 (ru) | Композиции антител и способы применения |